Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Blocking tumor-derived cytokine signaling in dendritic cells enables engineered dendritic cells to function as an antitumor vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4652 · Cited by 584 · cited 1×
“Animals Stat3mice (67) were bred with CD11c Cre [B6.”
MethodYang, X.-P., Ghoreschi, K., Steward-Tharp, S. M., Rodriguez-Canales, J., Zhu, J., Grainger, J. R., Hirahara, K., Sun, H.-W., Wei, L., Vahedi, G., et al. (2011) · Nature Immunology · doi:10.1038/ni.1995 · Cited by 583 · cited 1×
“Melanoma cells secrete numerous STAT3-activating cytokines that modulate immune cell function (31, 32), and previous studies show that STAT3 and STAT5 can have opposing activity on specific gene promoters (33).”
BackgroundGreter, M., Helft, J., Chow, A., Hashimoto, D., Mortha, A., Agudo-Cantero, J., Bogunovic, M., Gautier, E. L., Miller, J., Leboeuf, M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.027 · Cited by 433
AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMA
Lázár-Molnár, E., Hegyesi, H., Tóth, S., & Falus, A. (2000) · Cytokine · doi:10.1006/cyto.1999.0614 · Cited by 416 · cited 1×
“Upon stimulation of Id2 GM-DCs in culture with interleukin-6 (IL-6), IL-10, or vascular endothelial growth factor (VEGF), cytokines associated with B16 melanoma and a protumor microenvironment (34), we found a marked decrease in Id2 expression (Fig.”
BackgroundDendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function
Melillo, J. A., Song, L., Bhagat, G., Blazquez, A. B., Plumlee, C. R., Lee, C., Berin, C., Reizis, B., & Schindler, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902960 · Cited by 225 · cited 1×
“Together, these results indicate that STAT3 has an intrinsic role in mediating the immunoregulatory activity of GM-DCs, consistent with previous reports (29, 36, 37).”
ResultEsashi, E., Wang, Y.-H., Perng, O., Qin, X.-F., Liu, Y.-J., & Watowich, S. S. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.013 · Cited by 202
Self-citation
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
STAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129
Xiao, Y., Zou, Q., Xie, X., Liu, T., Li, H. S., Jie, Z., Jin, J., Hu, H., Manyam, G., Zhang, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161524 · Cited by 87
Self-citation
Metadata
- Authors
- Li, H. S., Liu, C., Xiao, Y., Chu, F., Liang, X., Peng, W., Hu, J., Neelapu, S. S., Sun, S.-C., Hwu, P., & Watowich, S. S.
- Venue
- Science Signaling
- Published
- 2016-09-27
- Volume
- 9
- Issue
- 447
- Pages
- ra94-ra94
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2525088754
- Cited by
- 22
- References
- 8
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.